OSTX News

OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Ready to Announce with Confidence?

OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary Ready to Announce with Confidence?

OS Therapies Enters into Warrant Inducement Agreements Ready to Announce with Confidence?

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of OS Therapies Incorporated (NYSE American: OSTX)

OS Therapies Provides First Half 2026 Corporate Outlook Ready to Announce with Confidence?

OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility

OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization

Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25